SIKs control osteocyte responses to parathyroid hormone

Citations Over TimeTop 10% of 2016 papers

Abstract

Parathyroid hormone (PTH) activates receptors on osteocytes to orchestrate bone formation and resorption. Here we show that PTH inhibition of SOST (sclerostin), a WNT antagonist, requires HDAC4 and HDAC5, whereas PTH stimulation of RANKL, a stimulator of bone resorption, requires CRTC2. Salt inducible kinases (SIKs) control subcellular localization of HDAC4/5 and CRTC2. PTH regulates both HDAC4/5 and CRTC2 localization via phosphorylation and inhibition of SIK2. Like PTH, new small molecule SIK inhibitors cause decreased phosphorylation and increased nuclear translocation of HDAC4/5 and CRTC2. SIK inhibition mimics many of the effects of PTH in osteocytes as assessed by RNA-seq in cultured osteocytes and following in vivo administration. Once daily treatment with the small molecule SIK inhibitor YKL-05-099 increases bone formation and bone mass. Therefore, a major arm of PTH signalling in osteocytes involves SIK inhibition, and small molecule SIK inhibitors may be applied therapeutically to mimic skeletal effects of PTH.

Related Papers

• → Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin(2007)1,327 cited
• → Osteocyte Deficiency in Hip Fractures(2011)43 cited
• → Osteocyte — A new target for the treatment of osteoporosis(2013)
• → Faculty Opinions recommendation of Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.(2008)